Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway

NCT03651765 is registered in ClinicalTrials.gov with Rhythm Pharmaceuticals, Inc. as lead sponsor.

NCT NCT03651765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03651765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Long Term Extension Trial of Setmelanotide (RM-493) for Patients Who Have Completed a Trial of Setmelanotide for the Treatment of Obesity Associated With Genetic Defects Upstream of the MC4 Receptor in the Leptin-melanocortin Pathway
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
July 15, 2018
Completion date
January 9, 2025
Enrollment
205 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

obesity associated with defects in leptin-melanocortin pathway